Recent News

• 03.10.2025 - Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.05.2025 - Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
• 02.05.2025 - Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment
• 01.22.2025 - Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
• 01.08.2025 - Ensysce Biosciences Issues Annual Shareholder Letter
• 12.10.2024 - Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
• 12.04.2024 - Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
• 12.04.2024 - Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
• 12.03.2024 - Ensysce Biosciences Announces 1-for-15 Reverse Stock Split
• 12.03.2024 - Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Recent Filings

• 03.10.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.10.2025 - 8-K Current report
• 03.10.2025 - EX-99.1 EX-99.1
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.04.2025 - 8-K Current report
• 12.03.2024 - 8-K Current report